Inbred mouse strains differ in their capacity to deiodinate iododioxin and iodothyronines, with strains segregating into high or low activity groups. Metabolism of iododioxin occurs via the type I iodothyronine 5'deiodinase (51DI), one of two enzymes that metabolize thyroxine (T4) to 3,5,3'-triiodothyronine (T3). Recombinant inbred strains derived from crosses between high and low activity strains exhibit segregation characteristic of a single allele difference. Hepatic and renal 5DI mRNA in a high (C57BL/6J) and low (C3H/HeJ) strain paralleled enzyme activity and concentration, in agreement with a recent report. 5DI-deficient mice had twofold higher serum free T4 but normal free T3 and thyrotropin. Brown adipose tissue 51DII was invariant between the two strains. Southern analyses using a 51DI probe identified a restriction fragment length variant that segregated with 51DI activity in 33 of 35 recombinant inbred strains derived from four different pairs of high and low activity parental strains. Recombination frequencies using previously mapped loci allowed assignment of the 5DI gene to mouse chromosome 4 and identified its approximate chromosomal position. We propose the symbol Diol to denote the mouse 51)I gene. Conserved linkage between this segment of mouse chromosome 4 and human HSAlp predicts this location for human Diol. (J. Clin. Invest. 1993. 92:1517-1528
Introduction
Thyroxine (T4)' must be deiodinated to 3,5,3'-triiodothyronine (T3) in order to be fully active under physiological condi- 1 . Abbreviations used in this paper: BAT, brown adipose tissue; BrAcT3, N-bromoacetyl-L-3,5,3'-triiodothyronine; 5DI, type I 5' deiodinase; 5DII, type II 5' deiodinase; I-CI3DpD, 2-iodo-3,7,8-trichlorodibenzo-p-dioxin; PTU, 6-n--propylthiouracil; RFLV, restriction fragment length variant; RI, recombinant inbred; T3, 3,5,3'-triiodothyronine; T4, thyroxine; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone (thyrotropin).
tions. Two enzymes catalyzing this reaction have been identified, the types I and II iodothyronine 5' deiodinases ( 5'DI and 5'DII). Recently one of these, the type I enzyme, has been cloned from rat and human liver ( 1, 2) . The enzyme contains selenocysteine in its catalytic site and mutation of the selenocysteine to cysteine leads to a marked decrease in the catalytic efficiency of the rat enzyme (3) . Experimental selenium deficiency leads to an increase in serum T4 and a decrease in serum T3 concentration in association with a reduction in hepatic and renal 5'DI activity (4, 5) . This occurs as a consequence of compensatory increases in thyroid-stimulating hormone (thyrotropin; TSH) secretion owing to the sensitivity of the hypothalamic-pituitary feedback system to circulating T3 (6, 7). Type I deiodination follows ping-pong, bisubstrate kinetics with a requirement for reduced thiol as second substrate (3). 6 -n-propylthiouracil (PTU) is a specific inhibitor of the 5 'DI and has been postulated to form a stable dead-end complex between the selenolyl iodide intermediate of the first half-reaction and the sulfhydryl group of the thiourea compound (3) .
In thyroidectomized rats given replacement T4, PTU inhibition of 5'DI causes marked hypothyroidism in the liver, which derives most of its T3 from plasma T3 (8) .
There are only a few examples of thyroid hormone resistance in humans which could potentially be attributed to a deficiency of 5'DI (9, 10) . Until recently, no animal models had been identified. Accordingly, it is difficult to develop an uncomplicated model of 5'DI deficiency, because both PTU administration and selenium deficiency could have other biochemical or physiological effects in the intact animal. We noted in studies of [12511] 2-iodo-3,7,8-trichlorodibenzo-pdioxin (iododioxin, ['251I]Cl3DpD) metabolism, that inbred mouse strains segregated into groups exhibiting high or low hepatic iododioxin deiodinase activity. In particular, hepatic deiodination of iododioxin was -20-fold lower in C3H/HeJ (C3H) than in C57BL/6J (B6) mouse strains. Subsequent studies showed that the differences in enzyme activity with respect to iododioxin were also found when [1251I ]T4 was used as substrate. Thus, it appeared that iododioxin was a substrate for the 5DI and that this enzyme was expressed at different levels in these two strains. We initiated the present collaborative study (a) to identify the mechanism by which 5'DI deficiency occurred, (b) to explore the effects of deiodinase deficiency on serum thyroid hormones, TSH, and type II deiodinase activity, and (c) to analyze the inheritance of 5 DI deficiency in recombinant inbred (RI) mouse strains by restriction fragment length variant (RFLV) analysis.
Preparation of microsomes. Mice were killed by cervical dislocation, and the livers were removed and homogenized with 9 vol of MDEN buffer (25 mM Mops, 1 mM DTT, 1 mM EDTA, and 0.02% sodium azide), and centrifuged at 10,000 g for 20 min. The supernatant fraction was made 10 mM in EDTA and centrifuged at 100,000 g for 1 h. The microsomal fraction was resuspended (equivalent to 1 g of liver/ml) in 0.25 M sucrose and stored at -80'C until use.
[125I] CI3DpD deiodinase assays. The standard assay consisted of a total incubation volume of 400 gl containing 9.5 gmol phosphate buffer (pH 7.4), 3 Mmol EDTA, 6.7 Mmol DTT, 300 fg bovine serum albumin, 12.5 ,g liver microsomal protein, and 10 Ml of DMSO containing the substrate (1 pmol of radiolabeled ['25ICl3DpD, .83 x 10' dpm plus unlabeled compound to give the desired concentration). The reaction was incubated at 370C in a shaker-water bath for 15 min unless otherwise indicated, terminated by the addition of 50 Ml 50% TCA, and placed on ice. The protein precipitate was removed by centrifugation, the supernatant was decanted, and 50 Ml of a solution containing 50% NH40H, 1 mg Na2S205, and 0.1 Mug Nal was added.
The solution was extracted with 2 ml of mixed hexanes and after freezing in a dry ice-ethanol bath, the organic layer removed by decanting. Extraction with hexanes was repeated twice more. in PE buffer in a final volume of50 Ml. Labeling was at ambient temperature for 10 min. and was terminated by addition ofan equal volume of electrophoresis sample buffer containing 2.5% SDS and 0.5 M 2-mercaptoethanol. Labeled proteins were analyzed by SDS-PAGE and autoradiography. Quantitation was performed both by densitometry (Computing Densitometer; Molecular Dynamics, Sunnyvale, CA) and by excision and counting ofthe -27-kD 5'DI bands, with closely agreeing results. Specific incorporation into deiodinase protein was determined by subtraction of nonspecific from total incorporation ( 13). Nonspecific incorporation was determined by quantitating the corresponding region from parallel gel lanes in which labeling of the 27-kD protein was completely inhibited by addition of excess unlabeled BrAcT3.
Northern blot analysis. RNA was isolated from liver and kidney by homogenizing tissues in guanidinium thiocyanate and centrifugation through cesium trifluoroacetate (Pharmacia Inc., Piscataway, NJ). Poly A+ RNA was prepared as described previously ( 14) . RNA samples (5 Mg) in 50% formamide and 1.3% formaldehyde were heated at 70°C for 5 min and electrophoresed on a 1.1% agarose gel containing 20 mM Mops (pH 7.0), 5 mM sodium acetate, 1 mM EDTA, and 1.3% formaldehyde. RNA was blotted to GeneScreen Plus (DuPont Co., Wilmington, DE), UV cross-linked, and probed with a rat 5 DI cRNA (1) , and the blot was washed at high stringency, with the final wash being in 0.1 X SSC, 0.1% SDS at 65°C. The blot was stripped by boiling and reprobed with a mouse ,B-actin cRNA. Quantitation ofthe blot was by densitometry.
Measurements of thyroid hormones and TSH. Serum T3 and T4 concentrations were quantitated by radioimmunoassays as previously described ( 15, 16 ( 18) . The resulting probes, which had a specific activity of> 3 X 108 cpm/ g, were used in hybridization to Southern blots as described previously ( 19) .
Isozyme typing. Mice were typed for the kidney isozyme hexose-6-phosphate dehydrogenase (Gpd-J) by the Genetic Quality Control Service ofthe Jackson Laboratory under the supervision ofDr. Richard Fox.
Probes. The full-length rat type I deiodinase cDNA plasmid clone in Bluescript KS ( 1 ) was used to probe Southern blots. Other probes used are described in Table X 
Statistical analysis. Estimated recombination frequencies (r) between gene pairs were obtained from the analysis ofRI strain data using the equation r = R/(4 -6R), where R is the ratio ofthe number ofRI strains with recombinant genotypes to the total number of RI strains typed (20) . Confidence limits of recombination frequencies obtained from RI data were calculated as described by Silver (21 (Fig. 2) . (Table II) .
Segregation ofiodothyroninedeiodinaseactivity in recombinant inbred mice. The strain distribution pattern permitted us to select recombinant inbred lines developed from parental strains in which one parent had high and one low deiodinase activity. Studies of mRNA expression. Since differences in mRNA levels could explain the lower 5 DI levels in C3H mice, we performed Northern analyses of 5 DI mRNA in the two strains (Fig. 3) . Quantitation of deiodinase RNA normalized to a f3-actin RNA revealed B6/C3H mRNA ratios of 9.3 in liver and 2.3 in kidney. The mRNAs of both strains were -2.1 kb. Slot blot analyses of tissues from three different animals of each strain showed similar differences, with the B6/C3H ratio approximately sevenfold for liver and twofold for kidney.
A comparison of 5)DI V,,,, BrAc [ '25I]T3 labeling, and mRNA levels between these two strains shows that, for each strain, a close correlation exists between enzyme activity, deiodinase protein, and mRNA (Fig. 4) . Thus, the 5 DI deficiency in the C3H mouse can be attributed to a decrease in the quantity ofmRNA for this enzyme, presumably due either to altered mRNA transcription, or stability, or both.
Serum thyroid hormone concentrations and TSH in sera of B6 and C3H mice. While there was no difference in the concentrations of total or free T3 in the two mouse strains, the serum total and free T4 concentrations in the C3H mice were approximately twice those of the B6 strain ( Table V) . The basal and TRH-stimulated TSH concentrations were also not different in the two strains of mice. As indicated in Methods, the results for the basal TSH concentrations, but not the TRHstimulated values, are confounded by displacement of [125II-rTSH from the antibody by both B6 and C3H sera. This activity is not affected by doses of exogenous T3 which suppress TSH. While the estimated basal TSH concentrations are therefore artifactually elevated, there was no difference in TSH concentrations in the C3H and B6 inbred strains using 25, 50, or 100 ml of serum in the radioimmunoassay. Fig. 3 , and is expressed in arbitrary units.
Inherited Type I Deiodinase Deficiency Studies ofType II deiodinase. A second enzyme, the PTUresistant 5 DII, also catalyzes conversion ofT4 to T3. Based on a number ofbiochemical studies, it is thought that this enzyme is the product ofa different gene from that ofthe type I enzyme and furthermore, that it is not a selenoprotein (26, 27) . We analyzed 5DII enzyme activity in pituitary and brain of C3H and B6 mice. The 5DII activities in these two organs were approximately half of those in the B6 strains (Table VI) . Because 5 DII activity is inhibited by T4 (28), this difference can Table III ) and CXB (cross of BALB/cBy and B6) RI strains. In order to increase the resolution of the TaqI variants, B6 and C3H DNAs were double digested with TaqI and other restriction enzymes and analyzed by Southern blotting. Double digests with TaqI and SstI yielded a common fragment of 2.8 kb and a variable fragment of either 2.5 kb (B6) or 2.6 kb (BALB and C3H). This difference was employed to type the CXB and BXH RI strains (data not shown). The SWXJ (cross of SWR/J and SJL/J) RI strains were typed with respect to an EcoRI variant. A TaqI RFLV was used to type the NX 129 (cross of NZB/ BINJ and 129/J) RI strains. All of the RI strain typings (RFLVs and activity variants described in the previous section) are summarized in Table VIII . There was complete concordance between the deiodinase RFLV and high or low deiodinase activity in 21 informative BXH and CXB RI strains. In the SWXJ RI strains, there was also concordance in all but two strains, SWXJ-11 and 12. The single SWXJ-12 mouse typed for the Diol RFLV appeared to be heterozygous. Of the two SWXJ-12 mice tested for deiodinase activity, one was clearly intermediate, while the other appeared to belong to the low activity class. In SWXJ-11, the single mouse tested for the RFLV was homozygous for the SJL/J allele, while the deiodinase activities of the two tested mice were intermediate. Since the SWXJ RI strains were not highly inbred at the time they were tested, residual heterozygosity might explain these anomalous results. We attempted to clarify this matter by testing two additional mice of both SWXJ-11 and SWXJ-12 for deiodinase activity and by typing the same mice for the deiodinase RFLV. Age and sex matched progenitor mice were analyzed simultaneously. Both strains were clearly intermediate in activity, and both were homozygous for the SJL/J deiodinase RFLV. The correct interpretation of the SWXJ-11 and -12 strains is unclear. The fact that these two strains exhibit an intermediate deiodinase activity suggests that activity is not 
The letters B, C, and H are used as generic symbols for alleles inherited from the C57BL/6 (By or J substrains), BALB/cBy, and C3H/HeJ progenitor strains, respectively. some 4 RFLV loci scored in the cross and the probes used are shown in Table X . The results shown in Relationship to the obesity-diabetes syndrome mutation. Because of the profound consequences of thyroid status on activity and basal metabolic rate and their similar map positions, we considered the possibility that the recessive mutant gene diabetes (gene symbol, db; for review, see reference 33) might be an allele at the Diol locus. This was tested by looking for a dissociation between the db mutation and its associated Diol RFLV haplotype. Since the original db mutation arose on a C57BL/KsJ, and had been transferred by successive rounds of backcrossing and intercrossing to the C3H.SW congenic strain background, we examined the two parental strains and the C3H.SW/Lt-db (N9, F8 generation) congenic strain by Southern blotting. The results showed that C57BL/KsJ was homozygous for Diod b, and both C3H.SW and C3H.SW-db were homozygous for Diol a (data not shown). Thus, at some point in the transfer of db to its new strain background or its subsequent propagation by brother-sister mating, a crossover must have occurred and become fixed in the congenic strain. Discounting the possibility of a rare intragenic recombination, this result excludes Diol as a candidate gene for db.
Discussion
The close correlation between the levels of iododioxin and iodothyronine deiodinase activities in inbred strains of mice, in conjunction with the biochemical properties, cofactor requirements, and subcellular fractionation behavior, indicated that for both classes of substrate the activity could be attributed to 5 'DI. Kinetic studies demonstrate that iodothyronines are competitive inhibitors of iododioxin deiodination (Fig. 1) , further evidence that both compounds are substrates for the same enzyme. The segregation of 5 'DI activity from progenitor mouse strains into RI strains exhibiting either high or low hepatic 5 DI activities allowed us to investigate the mechanism, genetics, and physiological function ofthe mouse 5 DI. For detailed studies of the etiology of the difference in 5'DI activity, the B6 (high) and C3H (low) inbred strains were examined in detail as representatives of the two phenotypes. The data presented in
Tables III and IV demonstrate that the difference in 5'DI activities with respect to T4 and rT3 can be attributed to a difference in the apparent Vm,, of the hepatic and kidney 5DI enzyme, with no difference in Km. The results in Table III show that this difference segregates in the BXH RI strains, which have activi- (4-5-fold) . The lower activity in C3H versus B6 and the differences between the RI strains are due to lower content ofa kinetically normal 5 'DI. The Northern blot studies (Fig. 3) illustrate that the difference in 5 DI activities can be explained by a difference in 5DI mRNA levels. The data in Fig. 4 (34) , placing it close to the complement 8-beta gene (C8b). It is also apparently close to the obese-diabetes syndrome mutant gene db. The latter gene has been the focus of intense interest as a model for human obesity and type II diabetes, and recently there has been a concerted effort to isolate the db gene by positional cloning. The possibility that db might be a mutant allele at the Diol locus was considered, but disproved based on the observation of a crossover event in a db congenic strain. Direct measurement ofthe deiodinase activity of liver homogenates of db/db and control mice yielded indistinguishable measurements, providing further indication ofthe distinctness ofthe two loci. Although the phenotype ofa mouse severely deficient in deiodinase activity can only be a matter of speculation, manifestations of thyroid insufficiency might be anticipated. In this regard, such a mouse might resemble the two known thyroid-deficient mice, hypothyroid (hyt) and congenital goiter (cog). The syndromes presented by these mutant mice do not include marked obesity or hyperglycemia. No hypothyroid mutant has yet been identified that maps to this region of chromosome 4 for which Diol can be considered a candidate gene. If such a mutant is subsequently identified and mapped to chromosome 4, the possible association with Diol should be apparent. The position of Diol in chromosome 4 of the mouse allows the prediction that the human homolog of Diol will map to HSA I p (34) . The segment of chromosome 4 homologous to HSA lp extends proximally from Jun (position 44) to Skv (position 77) distally, and therefore represents one of the largest uninterrupted regions of conserved linkage between the two species. The placement ofDiol within the chromosome 4 linkage map and the association of the a haplotype with the low activity phenotype will provide a valuable reference point for further mapping in RI strains.
What are the physiological consequences ofa 5-10-fold difference in 5 DI activity and what compensatory mechanisms occur in the intact animal? Data in Table V demonstrate that relative to the B6 mice, C3H strains have elevated serum total and free T4 but normal serum-free T3 and TSH concentrations. Quantitation of free hormones is required to establish this difference, since thyroid hormone binding abnormalities have been described in certain mouse strains, e.g., db/db, ob/ob, and dystrophic animals ( 16, 35 ) . The fact that serum-free T3 concentrations are normal in C3H animals would lead to a euthyroid state in those peripheral tissues (heart, liver, kidney, skeletal muscle) which depend predominantly on the plasma T3 for their intracellular hormone (36, 37) . This can account for the euthyroid phenotype of the C3H strain which shows none of the manifestations of hypothyroidism found in genetically hypothyroid mice such as those with the hyt or cog mutations. In the iodine-sufficient rat, 65-75% of the circulating T3 derives from a PTU-sensitive T4 5'-deiodination process, catalyzed by the 5'DI in liver and kidney (15, 37, 38) . The reInherited Type I Deiodinase Deficiency mainder originates from a combination of direct thyroidal T3 secretion and from PTU-insensitive T4 to T3 conversion (5DII). A similar analysis has not been performed in the mouse but it seems unlikely that this situation would be very different. The normal concentration of free T3 in sera of C3H mice presumably is due to the fact that, while the fractional conversion of T4 to T3 per day would be reduced, the higher serum-free T4 concentration permits normal daily T3 production. We speculate that T4 production rates could well be normal since the higher concentrations and reduced fractional clearance could balance each other. A reduction in inner ring deiodination of T3, also a function of the 5 DI enzyme, could also contribute to maintenance of normal circulating T3 concentrations.
An intriguing physiological question is how the hypothalamic-pituitary thyroid axis recognizes the requirement for higher serum T4 concentrations. In the rat, the degree ofsaturation of nuclear T3 receptors in the pituitary correlates most accurately with the rate of TSH secretion (6, 7, 39) . There are two sources of pituitary nuclear T3, that derived directly from the plasma and T3 derived from intrapituitary T4 to T3 conversion via the type II, PTU-insensitive mechanism (36, 37) . The 5DII enzyme differs from 5)DI in its lower V. and Km, and its very low sensitivity to inhibition by PTU or gold (27, 36) . Recent studies have suggested that 5 DII does not contain selenocysteine (26, 27) , and this activity is expressed in rat brown adipose tissue, which does not express 5DI (1). The level of 5DII is reduced when the serum T4 concentration is increased. This regulation probably occurs post-translationally by accelerating the degradation of the 5DII (40) . Thus, in hypothyroid animals, type II deiodinase activity increases, and after T4 injections, this activity falls (41, 42) .
It would therefore be anticipated that in C3H mice, the higher serum-free T4 concentration would cause a decrease in the activity of 5 DII, and this prediction was born out by the data presented in Table VI . In both cerebral cortex and in pituitary, 5DII activity was twofold lower in C3H than in B6 mice. A similar phenomenon has been identified in rats made selenium deficient (4, 43) . However, recent studies have shown that in hypothyroid animals, selenium deficiency does not reduce 5'DII activity (44) . Thus, in both the C3H strain and in intact selenium-deficient animals, the elevation in serum T4 can explain the decrease in 5 DII activity in brain and pituitary. This is further confirmed by the finding of normal 51DII activity in brown adipose tissue of C3H mice (Table VI) , an observation which also demonstrates that 5 DII is not the product of the Diol gene. Since the 50% decrease in 51DII activity in the brain and pituitary is balanced by the elevation in serum T4 concentration, one would predict that the T3 contribution from this source to pituitary nuclear T3 would be quite similar to that of the B6 animals. Therefore TSH secretion would be the same. The data in Table V show that TSH concentrations are not different in the two strains. Given all of these internal compensatory changes, one would expect a euthyroid state in the C3H strain, wh1ich is what has been observed.
After our submission of this manuscript, Schoenmakers et al. (45) reported 5'DI activities, mRNA, and serum hormone levels in C3H and B6 mice, initiating their studies after informal discussions with one of us (A.P.). In contrast to our findings, they observed highly variable hepatic 51DI activities in C3H mice, though the mean was 18% of that in the B6 strain. They also found that the levels of5 DI mRNA and BrAc [1251]T3-labeled 28-kD protein were proportionately reduced in C3H animals with low 51DI activity. However, again in contrast to our results, serum total T4 concentrations were not significantly different between C3H and B6 strains, presumably due to the heterogeneity in 51DI activities. We have no explanation for the disparate 5 DI results in this study, since we have not observed, in over 40 C3H mice, 51DI activity or mRNA levels which overlap with the range in B6 animals.
Neither 51DII activities, free hormone concentrations, or serum TSH results were reported by Schoenmakers et al., though serum rT3 was significantly higher in the C3H than in the B6 mice, consistent with the reduced 51DI activity in this strain.
A putative Type I deiodinase defect has been described in one family and in one individual which may be analogous to the 51DI differences seen in the C3H and other low 51DI strains (9, 10) . In these individuals, serum total and free T4 are elevated, and serum T3 and TSH are normal. These patients are also clinically euthyroid, indicating that the predominant manifestation of this defect is in the elevated serum-free T4. The predicted location of the Diol gene on human chromosome 1 may aid in characterization of such defects as due to alterations in the 51DI gene. Furthermore, it is conceivable that the relatively broad normal range of serum free T4 concentrations found in humans could be explained by differences in the concentration or function of the 51DI enzyme. Such differences would be compensated internally and be reflected only in variable concentrations of free T4, all associated with a normal serum free T3 and TSH.
In addition to the allelic differences in type I deiodinase described herein, a number of other genetic differences between the C3H, B6, and BALB inbred strains have been described. C3H exhibits 20-50-fold higher susceptibility than B6 to chemically induced hepatocarcinogenesis (46) . This difference appears to be due to increased responsiveness of C3H liver cells to c-Ha-ras gene mutations. However, variations in tumor formation do not segregate with 51DI, as BALB mice fall into the low tumor susceptibility category, like B6, whereas for Diol, BALB segregates with C3H. Differences in atherosclerotic plaque formation and plasma HDL levels in response to a high fat diet have also been studied extensively, with B6 exhibiting the highest susceptibility and lowest HDL, BALB intermediate (plaque formation and HDL), and C3H the most resistant, with the highest HDL. The lack of clear segregation in BALB mice suggests that the plaque formation differences are due to multigenic effects, and allelic differences correlating with atherosclerosis susceptibility have been described in apolipoprotein II on chromosome 1 (47, 48) , and in a newly identified gene, Ath-2 (49). Whether or not the 51)I polymorphism also contributes to plaque formation is unknown.
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